Tolerability profile of atypical antipsychotics in children and adolescents

Pediatric Drugs

Volumn 3, Issue 12, 2001, Pages 927-942

  Stigler, K A ^a   Potenza, M N ^b   McDougle, C J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; DRUG EFFECT; DRUG TOLERANCE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; LIVER TOXICITY; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; TARDIVE DYSKINESIA;

EID: 0035692771     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103120-00005     Document Type: Review

References (95)

1. Do novel antipsychotics have similar pharmacological characteristics: A review of the evidence
2. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
3. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
4. D-4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs
5. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications
6. Use of atypical neuroleptics in child and adolescent psychiatry
7. Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison
8. Clozapine for schizophrenia
9. An open trial of clozapine in thirty-six adolescents with schizophrenia
10. Own experience (1989-1994) in the treatment of adolescent schizophrenic paranoid syndromes with leponex produced by Sandoz Company
11. Elevated prolactin in pediatric patients on typical and atypical antipsychotics
12. Results of treatment with clozapine in schizophrenic adolescents
13. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia
14. Clozapine for schizophrenia
15. Clozapine treatment in childhood-onset schizophrenia
16. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: Association with response
17. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia
18. Anti-aggressive effects of clozapine in children and adolescents
19. Clozapine treatment in very early onset schizophrenia
20. Clinical effects of clozapine on autistic disorder
21. Clozapine in the treatment of a young adolescent with schizophrenia
22. Eosinophilia, clozapine, and pancreatitis
23. Clozapine treatment of bipolar disorder in a young adolescent
24. Clozapine for early developmental delays with childhood-onset schizophrenia: Protocol and 15-month outcome
25. Clozapine medication in adolescents
26. Childhood-onset schizophrenia: An NIMH study in progress
27. Paediatric uses of atypical antipsychotics
28. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
29. Novel antipsychotics and new onset diabetes
30. Ketoacidosis as a side effect of clozapine: A case report
31. Clozapine and associated diabetes mellitus
32. Diabetic ketoacidosis associated with clozapine treatment
33. Biochemical profile of risperidone, a new antipsychotic
34. Risperidone in adolescents with schizophrenia: An open pilot study
35. Risperidone in adolescents
36. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects?
37. Risperidone effects in treatment-resistant adolescents: Preliminary case reports
38. Risperidone in childhood schizophrenia
39. Case study: Risperidone in children and adolescents with schizophrenia
40. Risperidone for treatment of childhood schizophrenia
41. Risperidone in children with schizophrenia
42. Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up
43. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study
44. An open trial of risperidone in young autistic children
45. Use of risperidone in pervasive developmental disorders: A case series
46. Case study: Risperidone treatment of children and adolescents with developmental disorders
47. Risperidone in the treatment of two very young children with autism
48. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report
49. Risperidone as a treatment for Tourette's syndrome
50. Clinical experience with risperidone
51. A double-blind pilot study of risperidone in the treatment of conduct disorder
52. Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study
53. Risperidone: Induced hepatotoxicity in children and adolescents: A chart review study
54. Enuresis with combined risperidone and SSRI treatment
55. Weight gain associated with risperidone
56. Case study: Risperidone-induced hepatotoxicity in pediatric patients
57. Risperidone side effects
58. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent
59. Risperidone and tardive dyskinesia
60. Risperidone for negative symptoms
61. Tics with risperidone withdrawal
62. Risperidone-induced neuroleptic malignant syndrome
63. Risperidone-induced mania
64. Induction of mania by risperidone resistant to mood stabilizers
65. Mania induced by risperidone: Dose related?
66. Olanzapine in Tourette syndrome
67. Mood stabilizer augmentation with olanzapine in acutely manic children
68. Olanzapine in the treatment of bipolar-disorder in juveniles
69. Olanzapine in PDD
70. Olanzapine in Tourette's disorder
71. An open label study of olanzapine in children with PDD
72. Open-label olanzapine treatment in five preadolescent children
73. Olanzapine for autistic disorder with hyperactivity
74. Olanzapine in the treatment of early onset schizophrenia in children and adolescents
75. Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: An open-label pilot study
76. Olanzapine in adolescents with psychotic disorder
77. Olanzapine in Tourette's disorder
78. Olanzapine in the treatment of adolescent acute mania: A report of seven cases
79. Childhood -onset schizophrenia: An open-label study of olanzapine in adolescents
80. Blind, controlled, long term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
81. Atypical antipsychotic drugs and long-term outcome in schizophrenia
82. Diabetic ketoacidosis with olanzapine treatment
83. Mania associated with olanzapine
84. Induction of manic symptoms by novel antipsychotics
85. Olanzapine-induced mania
86. ICI 204,636 (seroquel), a dibenzothiazepine atypical antipsychotic: Review of preclinical pharmacology and highlights of phase II clinical trials
87. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine in adolescents with selected psychotic disorders
88. Open-label quetiapine in the treatment of children and adolescents with autistic disorder
89. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
90. Quetiapine for refractory schizophrenia
91. Quetiapine for refractory mania in a child
92. Quetiapine in adolescent psychosis
93. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone
94. Ziprasidone (CP-88, 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
95. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study